Plasma cholesteryl esters, synthesized in the high density lipoproteins (HDL), may be transferred to other lipoproteins by a cholesteryl ester transfer protein (CETP). We found a twofold increase in mass transfer of cholesteryl ester from HDL to apoBcontaining lipoproteins in incubated hypercholesterolemic rabbit plasma compared with control. There was a two-to fourfold increase in the activity of CETP, measured in an isotopic assay in hypercholesterolemic plasma. A CETP-like molecule was isolated in increased amounts from hypercholesterolemic plasma. Incubated plasma from four dysbetalipoproteinemic subjects also showed an increase (threefold) in cholesteryl ester mass transfer, compared with normolipidemic controls. There was a twofold increase in the activity of CETP, assayed in whole or lipoproteinfree plasma. Thus, there is increased transfer of cholesteryl esters from HDL to potentially atherogenic apoB-containing lipoproteins in dyslipidemic rabbit and human plasma. The enhanced transfer results in part from increased activity of CETP, possibly reflecting an increase in CETP mass.
Introduction
During incubation of plasma there is transfer of cholesteryl esters from high density lipoproteins (HDL) to triglyceride-rich very low density lipoproteins (VLDL) (1) . The transfer ofcholesteryl esters is mediated by a plasma cholesteryl ester transfer protein (CETP)' (2) . The activity of CETP results in redistribution of cholesteryl esters, synthesized within HDL by lecithin:cholesterol acyltransferase, to VLDL and ultimately to low density lipoproteins (LDL) (3) . Since remnants of triglyceride-rich lipoproteins and LDL may be removed from plasma by hepatic receptors (4) , it has been postulated that the transfer of cholesteryl esters within plasma serves as part of a chain of events mediating the transport of cholesterol from peripheral tissues back to the liver (3, 5) , a process called reverse cholesterol transport. In several human diseases associated with accelerated atherosclerosis a defect in the transfer ofcholesteryl esters from HDL subpopulations to apoB-containing lipoproteins has been described (6, 7), suggesting that the defective transfer of cholesteryl esters in plasma may contribute to atherogenesis. On the other hand, it is also Address reprint requests to Dr. Tall. Receivedfor publication 13 May 1986 and in revisedform 5 December 1986. 1 . Abbreviations used in this paper: CETP, cholesteryl ester transfer protein; LCAT, lecithin:cholesterol acyltransferase.
possible that the transfer of cholesteryl esters may contribute to the formation of atherogenic, cholesteryl ester-rich apoB-containing lipoproteins, such as chylomicron or VLDL remnants.
In human dysbetalipoproteinemia or in the cholesterol-fed rabbit, the hepatic uptake of VLDL and chylomicron remnants may be, respectively, defective (4) or saturated (8) , leading to accumulation ofcholesteryl ester-rich remnants (called f3-VLDL) in plasma. The (-VLDL may be taken up by an arterial wall macrophage receptor (4) , leading to foam cell formation. To assess a potential contribution of endogenous plasma lipid transfer mechanisms to the accumulation of cholesteryl esters in atherogenic lipoproteins, we have measured the transfer of cholesteryl esters from HDL to apoB containing lipoproteins in incubated hyperlipidemic plasma, and have related the findings to the activity of the plasma CETP.
Methods
Animals. White New Zealand male rabbits were placed on diets of chow or chow supplemented with 0.5% cholesterol and 3% partially hydrogenated soybean oil. Blood was obtained in heparinized tubes from an ear vein of control or hypercholesterolemic rabbits after 12-20 wk on the diet. Plasma was separated immediately and analyzed within 48 h.
Human subjects. The study subjects were attending the Columbia University Arteriosclerosis Specialized Center of Research (SCOR) Core Clinic or the Lipid Clinic of The Rockefeller University. Plasma was obtained from four subjects with dysbetalipoproteinemia (also called type III hyperlipidemia). In each case isoelectric focusing ofthe patients' VLDL apoproteins showed the apoE-2/E-2 phenotype. Patient 1 was a 30-yr-old male with plasma lipids (mg/dl): cholesterol 657, triglycerides 705, VLDL cholesterol 414, VLDL triglycerides 567, HDL cholesterol 19. He had palmar xanthomata but no clinical evidence ofcardiovascular disease. He was studied at the initial visit then again after 4 mo of treatment with gemfibrozil, when his plasma cholesterol was 506 and triglycerides 379 mg/dl. Patient 2 was a 44-yr-old male with plasma lipids (mg/dl): cholesterol 321, triglycerides 318, VLDL cholesterol/triglycerides = 0.37, HDL cholesterol 37. He had a history of eruptive xanthomata but no clinical cardiovascular disease. He was studied at initial visit while taking clofibrate and also 4 episodes of eruptive xanthomata, and at the time ofblood sampling had several buttock lesions. She had mild fasting hyperglycemia but no clinical cardiovascular disease. A fifth patient with the apoE-2/E-2 isoform pattern but with normal plasma lipids was also studied. This 51-yr-old postmenopausal woman with peripheral vascular disease presented initially with dysbetalipoproteinemia but had responded to treatment with diet and gemfibrozil; at the time of study her plasma lipids (mg/dl) were: cholesterol 170, triglycerides 70, VLDL cholesterol 15, LDL cholesterol 77 and HDL cholesterol 78. Normolipidemic healthy volunteers (plasma cholesterol < 250 mg/dl; triglycerides < 150 mg/dl) were obtained from Medical Center Personnel. The control subjects were not taking medication and were matched for sex and approximately for age with the study subjects. Blood was collected in NaEDTA containing tubes and plasma was separated immediately by low-speed centrifugation.
Lipoproteins. Plasma LDL (1.02-1.063 g/ml) and HDL (1.063-1.21 g/ml) were isolated by sequential preparative ultracentrifugation at 10C and 40,000 rpm in a Ti 50.3 rotor. Human HDL-3 containing radiolabeled cholesteryl esters was prepared exactly as described previously (9) . The HDL contained 98% of radioactivity in cholesteryl esters and 2% in cholesterol. The specific activity was -10,000 dpm/nmol cholesterol. Inhibitors of plasma LCAT were not employed during the isolation of lipoproteins.
Cholesteryl ester mass transfer in incubated plasma. Incubations of plasma to determine net mass transfer of cholesteryl ester were usually begun within 2 h of venesection. However, similar results were obtained when plasma samples were analyzed after 48 h of storage at 4VC. The mass transfer of cholesteryl esters from HDL to apoB-containing lipoproteins (Figs. 1 and 7 in Results) was measured as described previously (9) . Briefly, plasma was incubated at 4VC or at 370C in a metabolic shaker, in the presence of 2 mM dithionitrobenzoic acid (DTNB) to inhibit plasma lecithin:cholesterol acyltransferase (LCAT). The addition of DTNB does not influence the initial rate of cholesteryl ester transfer measured in incubated plasma (6, 9) . At each time point an aliquot was removed, chilled on ice then the apoB-containing lipoproteins of the sample were precipitated with 0.1 vol of heparin/MnCl2 to give final concentrations of MnCI2 (0.092 M) and heparin (1.3 mg/ml) (10) . This concentration of MnCl2 results in very little precipitation of apoE-containing HDL (11) . The mass of cholesterol and cholesteryl esters remaining in the supernatant fraction was determined in pentuplicate. The transfer of cholesteryl esters into the apoB containing lipoproteins was calculated from the progressive decrease in mass of supernatant cholesteryl esters.
Isotopic assay to measure activity of CETP. The activity of CETP (Figs. 2-4, 8, 9 in Results) was measured in small aliquots of diluted plasma or in plasma fractions following the addition of HDL (10 Mg total cholesterol, 10,000 cpm cholesteryl ester radioactivity) and an excess of acceptor lipoprotein (human LDL containing 0.25 mg cholesteryl esters). The samples were diluted to a final volume of 250 M1 with 50 mM Tris-saline, 2 mM EDTA, pH 7.4, and incubated in a metabolic shaker at 37°C, usually for 2 h. The transfer of cholesteryl ester radioactivity was calculated from the amount of supernatant radioactivity remaining after precipitation ofthe LDL, subtracted from that ofa control sample containing LDL and radiolabeled HDL but no source of cholesteryl ester transfer activity. These Purification ofCETP. Human plasma CETP was purified about 500-fold from pooled Blood Bank plasma through the carboxymethylcellulose step (12) . The active carboxymethylcellulose fraction was then incubated with a synthetic lipid emulsion containing egg phosphatidylcholine, triolein and oleic acid, and the mixture was subjected to chromatography on a 40-cm column of Sepharose 4B. Homogeneous, active CETP was bound to the emulsion; active CETP could be released from the emulsion by delipidation. Based on activity the CETP was purified 55,000-fold relative to the plasma d > 1.21-g/ml fraction. Further details of this procedure will be published elsewhere (13) . A similar emulsion binding procedure was employed to obtain partially purified rabbit CETP, except that the emulsion was incubated with active fractions obtained after chromatography of plasma on a 170-cm column of 10% agarose. The active fractions were pooled, concentrated, incubated with the emulsion then chromatographed on Sepharose 4B columns, as described above. The CETP was visualized in 0.1 % SDS, 6/16% gradient polyacrylamide slab gels, stained with Coomassie Brilliant Blue. The gels were scanned at 525 nm using a model 1038 gel scanner (Helena Laboratories, Beaumont, TX). The intensity of staining was shown to be proportional to the mass of CETP in the range employed.
Tissue culture studies. Monolayers of macrophage-like J774 cells were plated, grown and maintained as described previously (14) . 1 d after plating, the cells were washed twice with phosphate-buffered saline and then incubated in I ml of Dulbecco's Modified Eagle's medium containing 0.1% BSA and the appropriate lipoprotein fraction (at 100 Mg cholesterol/ml). The cells were then washed, extracted and analyzed for cholesterol and cholesteryl ester mass as described (14) .
Analytical methods. In plasma fractions cholesterol and total cholesterol were determined by an enzymatic method and cholesteryl ester was calculated by difference and is expressed as the mass (in micrograms) of cholesterol plus esterified fatty acid (15, 16) . Phosphorus was determined by the method of Bartlett (17) . Results are given as mean±SEM values, and the significance of the differences of mean values is assessed by the Student t test.
Results
Cholesteryl ester transfer in hypercholesterolemic rabbit plasma.
The transfer of cholesteryl esters from HDL (heparin/MnCl2 supernatant) to apoB containing lipoproteins was increased in hypercholesterolemic rabbit plasma, compared with control rabbit plasma. During a 6-h incubation the mass transfer was 23.8±4.1 ,tg cholesteryl ester/ml plasma in the control rabbits and 48.6±6.9 Mg cholesteryl ester/ml plasma in the cholesterolfed rabbits (n = 6, difference significant, P < 0.01 by t test).
Conversely, the initial HDL cholesteryl ester mass (heparin/ MnCl2 supernatant) was lower in the hypercholesterolemic rabbits (19.6±5.3 mg/dl plasma) than in the controls (28.5±3.1 mg/dl).
To assess a possible role of the CETP in the stimulated cholesteryl ester transfer, the d > 1.063-g/ml fraction (containing the endogenous HDL and CETP) was recombined with a common acceptor lipoprotein, human VLDL (Fig. 1 ). The d > 1.063-g/ml fraction from hypercholesterolemic rabbit plasma caused a 2-to 2.5-fold greater stimulation of cholesteryl ester transfer at all levels ofacceptor lipoprotein, suggesting that the d> 1.063 g/ml-fraction was largely responsible for the enhanced cholesteryl ester transfer of hypercholesterolemic rabbit plasma. Furthermore, the d < 1 .063-glml fractions ofhypercholesterolemic and control rabbit plasma caused equal stimulation of cholesteryl ester transfer when recombined with the d > 1.063-g/ml fraction of control plasma (not shown).
Measurements ofCETP activity in rabbit plasma. The above results suggested the possibility of increased activity of CETP in hypercholesterolemic plasma. The activity of CETP was measured in an isotopic assay following the addition of standardized substrate lipoproteins to various fractions. In dose-response experiments, there was a three-to fourfold increase in CETP activity in hypercholesterolemic plasma, or in the d > 1.2 1-g/ml fraction of hypercholesterolemic plasma ( Fig. 2 A (C) or hypercholesterolemic (HC rabbit plasma. 5 ml plasma from a chow-fed or cholesterol-fed rabbit were centrifuged at 1.063 g/ml for 20 h at 40,000 rpm in a 50.3 rotor. The bottom 2 ml was removed, dialyzed against Tris-saline, EDTA, then aliquots were reconstituted with different amounts of pooled human VLDL to give the final concentration of triglyceride shown on the x axis. DTNB was added to give a final concentration of 2 mM, the samples were incubated 6 h at 370C, then the VLDL was precipitated with heparin/MnCI2. The transfer of CE mass into VLDL was calculated from the CE mass remaining in the supernatant, and is expressed as ,ug CE/ml of d > 1.063 fraction. The results are the mean±SEM values, from four experiments, each conducted in pentuplicate using different plasma samples.
(> 10-15%). A similar increase in CETP activity in lipoproteinfree plasma from hypercholesterolemic rabbits was also demonstrated in time course experiments, where the activity increased linearly with time during the 120-min assay for both control and hypercholesterolemic samples. The similar recovery of CETP activity in plasma and lipoprotein-free plasma ( stantially influence the measured activity. The absence of endogenous stimulators or inhibitors to account for the differences in CETP activity was also shown in mixing experiments, which resulted in an averaging of the activities of the control and hypercholesterolemic plasma. These results show increased activity of CETP in hypercholesterolemic plasma, independent of endogenous lipoproteins. Distribution of cholesteryl ester transfer protein in rabbit plasma. Prior studies have shown alterations in the activity of CETP related to changes in its binding to the plasma lipoproteins (9, 18) . To determine the distribution of CETP, plasma was analyzed by agarose chromatography and the activity of CETP was measured in individual column fractions. The assay was conducted with a small aliquot of each column fraction, which gave an activity within the linear range of the assay (inset, Fig.   3 A) ; under these conditions 80% of CETP activity of control or hypercholesterolemic plasma was recovered in the column fractions. In both control and hypercholesterolemic rabbit plasma ( Fig. 3 B and C) , the CETP eluted in a similar position, between the peaks of HDL and of purified human CETP (Fig.  3 A) . In 14 similar experiments, there was two-to fivefold greater CETP activity in the hypercholesterolemic samples. The following variables had no effect on the relative distributions or activ- (19), we considered the possibility that CETP was in fact bound to (3-VLDL in native plasma but became dissociated from the particles during the prolonged conventional chromatography procedure. To evaluate this possibility the hypercholesterolemic rabbit plasma was subjected to rapid chromatography using a Superose-12 column. The void fractions eluted in 7 min and the total profile was completed in 16 min (Fig. 4) . However, the distribution of cholesterol and of CETP activity was very similar to that obtained by the slower conventional chromatography. In another set of experiments, hypercholesterolemic rabbit plasma was analyzed by conventional chromatography on short (10 cm) columns of 2% agarose, using rapid flow rates. Although the resolution of proteins and lipoproteins was poor, the major lipoprotein fraction (carrying 85% of lipoprotein cholesterol) had eluted in 5 min and carried no CETP activity, while the active fractions eluted towards the end of the profile (not shown). Finally, the apoBcontaining lipoproteins ofhypercholesterolemic or control rabbit plasma were precipitated with heparin/MnCl2, and immediately sedimented by low speed centrifugation. The supernatant fractions, containing the HDL and CETP, were subjected to chromatography on the long 10% agarose columns. The precipitated sample was devoid of cholesterol-containing lipoproteins in the void fractions but displayed a peak of HDL cholesterol (not shown). The distribution and amounts of CETP activity recovered in unprecipitated and precipitated samples were almost identical, indicating that CETP did not co-precipitate with the (O-VLDL fraction. Thus, several approaches failed to show measurable binding of CETP by fl-VLDL in plasma. 7 .5 . Mass of rabbit CETP bound to a synthetic lipid emulsion.
To assess the possibility that the increased activity of CETP in hypercholesterolemic rabbit plasma was due to an increase in CETP mass, column fractions containing CETP activity (Fig.  3) were pooled, concentrated, and incubated with a synthetic lipid emulsion. The emulsion was purified on short agarose columns and the CETP bound to the emulsion was assayed for activity and visualized in SDS polyacrylamide gels (Fig. 5) . There was similar recovery of CETP activity through the concentration and binding steps for control and hypercholesterolemic samples (-60%). On the gels the rabbit CETP migrated in a similar position to punified human CETP for both control and hypercholesterolemic samples, but was 2.5 times more intense in the hypercholesterolemic sample, as assessed by scanning the gels. Similar results were obtained in experiments conducted with four different sets of control and hypercholesterolemic rabbit plasma. The band below CETP (Fig. 5 C) Z inactive). The plasma was analyzed by chromatography on long columns of 2% agarose in order to separate the larger and smaller subclasses of(3-VLDL (21, 22) . In four separate experiments the incubation resulted in an increase in mass of cholesteryl esters in both the turbid void-eluting fractions (large f3-VLDL), and in the later nonturbid fraction, designated as fractions 1 and 2 in Fig. 6 . There was a decrease in mass of cholesteryl esters in the region of smallest particles, where HDL elutes on this column, suggesting transfer from HDL to both subpopulations of f3-VLDL. There was an increase in the total mass of cholesteryl esters in the incubated sample, with a corresponding reduction in unesterified cholesterol (not shown), indicating new synthesis by LCAT. In a similar experiment analyzed by chromatography on the 10% agarose columns, a similar profile to that shown in Fig. 3 was obtained for the sample incubated at 40C (transfer inactive), while the sample incubated at 370C (transfer active) showed an increase in cholesteryl ester mass in the void eluting #-VLDL fractions, and a pronounced depletion of cholesteryl esters across the entire HDL peak (not shown). A similar redistribution of cholesteryl ester mass was observed in a sample incubated in 2 mM DTNB to inactivate LCAT. In further experiments the distribution of LCAT was determined in control and hypercholesterolemic rabbit plasma analyzed by chromatography on I010% agarose, using the method described (23). About 90% of endogenous LCAT activity was associated with the major peak of HDL, and < 10% was found in the void-eluting VLDL or 13-VLDL fractions. Analysis of LCAT and cholesteryl ester transfer activities in the same agarose column profiles of normal or hypercholesterolemic plasma showed that the peak of CETP activity eluted later in the profile, clearly separated from the peak of LCAT activity. Thus, the increase in cholesteryl ester mass in the f3-VLDL containing fraction resulted from cholesteryl ester transfer and not from synthesis by LCAT associated with the fl-VLDL.
The ability of the different fractions of fl-VLDL to cause accumulation of cholesteryl esters in cultured macrophages was examined. Both fractions of fl-VLDL caused pronounced cholesteryl ester accumulation in the macrophagelike J774 cells, as expected from previous studies using mouse peritoneal macrophages (20) . After incubation with different lipoprotein fractions (see Fig. 6 ), using the same total cholesterol concentration in the medium (100 ,g cholesterol/ml), the masses of cellular cholesteryl ester (ag/mg cell protein) were: control (no lipoprotein) (Fig. 6) was too small to allow this to be verified experimentally.
Cholesteryl ester transfer in human dysbetalipoproteinemia.
In human dysbetalipoproteinemia, there is accumulation of apoB-and apoE-containing chylomicron and VLDL remnants in plasma as a result of defects in apoE which cause impaired removal of these particles by hepatic receptors (4) . As in hypercholesterolemic rabbit plasma the accumulating remnant lipoproteins can deposit cholesteryl esters in macrophages and thus may be atherogenic (20, 21) . Fresh plasma from patients with dysbetalipoproteinemia or from normolipidemic controls was incubated in order to determine cholesteryl ester transfer. There was a pronounced increase in the mass transfer of cholesteryl esters from HIDL to apoB-containing lipoproteins in the dysbetalipoproteinemic subjects, compared to the controls (Fig. 7) . In plasma incubated for 2 or 6 h, there was an approximately Figure 7 . Cholesteryl ester transfer from HDL to apoB-containing lipoproteins in incubated plasma in patients with dysbetalipoproteinemia (HC) and in normolipidemic control subjects (C). Fresh plasma was incubated in 2 mM DTNB for the indicated times and the mass transfer of cholesteryl ester into apoB-containing lipoproteins was measured as described in Methods. The values shown are the mean±SEM results of eight experiments performed on plasma samples collected on six different occasions from four patients with dysbetalipoproteinemia. In each experiment the abnormal plasma was compared with plasma from a different normolipidemic control subject. The difference of the means was significant (P < 0.01) at the 6-h time point.
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.0 threefold greater transfer of cholesteryl esters in the dysbetalipoproteinemic subjects (Fig. 7) . The values for the control subjects were similar to those obtained previously in eight other normolipidemic controls (9) . An increased transfer of HDL cholesteryl ester mass into d < 1.063-g/ml lipoproteins was also documented after ultracentrifugal separation ofthe lipoproteins (3.5-fold greater transfer in the dysbetalipoproteinemic subjects). Incubation of plasma from a treated normolipidemic patient with the apoE-2/E-2 phenotype and previous dysbetalipoproteinemia revealed a similar cholesteryl ester transfer rate (25 ,gg/ ml plasma per 6 h) to simultaneous control normolipidemic plasma.
Activity of CETP in dysbetalipoproteinemic plasma. There was an approximate twofold increase in the activity of CETP measured in whole or lipoprotein-free plasma from dysbetalipoproteinemic subjects compared to control (Fig. 8) . Similar increases in CETP activity were obtained using plasma from three different dysbetalipoproteinemic patients. Although the results of Fig. 8 suggested slightly greater activity in lipoproteinfree plasma compared to whole plasma, this was not found in other similar experiments. When the activity ofCETP was measured in mixed samples of control and hyperlipidemic plasma there was an averaging ofactivities (not shown), which is inconsistent with an effect of activators or inhibitors.
Distribution ofplasma CETP in human dysbetalipoproteinemia. Plasma from patients with dysbetalipoproteinemia or from normolipidemic controls was subjected to agarose chromatography and the activity ofCETP was measured in individual column fractions. In normolipidemic plasma CETP activity was found to elute in a region corresponding to smaller HDL particles; a lesser, variable amount of CETP was recovered in a similar region to purified CETP (Fig. 9 A) . In dysbetalipoproteinemic plasma there was an increased amount of lipoprotein cholesterol in or near the void-eluting fractions. Also, the HDL cholesterol was reduced and eluted later in the column profile (Fig. 9 B) . In nine paired comparisons of column profiles of dysbetalipoproteinemic plasma (obtained from four patients on six different occasions) with plasma from nine normolipidemic control subjects, the former showed a 1.83±0.18 times greater total cholesteryl ester transfer activity compared with the latter (P < 0.01). This increased amount of CETP activity was not predominantly associated with the void-eluting lipoproteins, but rather was recovered in a later region of the column profile, Figure 9 . Agarose column distribution of CE transfer activity in human plasma, (A) normolipidemic control subject, (B) dysbetalipoproteinemic subject and (C) normolipidemic and dysbetalipoproteinemic subjects analyzed at pH 5.5. In (A) and (B) 3 ml fasting plasma was analyzed by chromatography on a 170-cm column of 10% agarose at pH 7.4. Fractions of 2.5 ml were collected. To 0.5 ml of each fraction was added LDL (0.1 mg protein) and HDL (10,000 cpm CE radioactivity, 10 jg CE) and the samples were incubated for 5 h at 370C then precipitated with heparin/MnCl2. The amount of CE radioactivity transferred into apoB-containing lipoproteins/ml fraction is shown on the yaxis. In (C) 3 corresponding to very small HDL particles (Fig. 9 B) . Since it is possible that the measurements of CETP activity were altered by the endogenous lipoproteins present in the column fractions, the activity of CETP dissociated from endogenous lipoproteins at pH 5.5 (9) was also assessed. Assayed in the lipoprotein-free fractions of the column profile, the activity of CETP was increased 2.5-fold, compared with normolipidemic plasma (Fig.  9 C) . Plasma from a normolipidemic apoE2/E2 patient (with treated dysbetalipoproteinemia) showed a similar distribution and amount ofCETP activity to a normolipidemic control, when analyzed by agarose chromatography (not shown). This suggests that the changes in cholesteryl ester transfer in dysbetalipoproteinemia are secondary to the hyperlipidemia.
Discussion
In the present report we have documented a pronounced stimulation of the transfer of cholesteryl esters from HDL to potentially atherogenic apoB-containing lipoproteins in the cholesterolfed rabbit and in human dysbetalipoproteinemia. The increased cholesteryl ester transfer resulted in part from increased activity of CETP. In the hypercholesterolemic rabbit the increased activity was shown to reflect an increased mass of CETP. Son and Zilversmit (24) recently reported an increase in cholesteryl ester transfer activity in hypercholesterolemic plasma obtained from Watanabe or cholesterol-fed rabbits. Also, an increase in cholesteryl ester transfer activity was found in the delipidated plasma of an uncharacterized group of hyperlipidemic subjects (25) .
However, we have observed that the two-phase solvent delipidation method employed in these studies (25) In the present study an increase in activity of CETP was documented in an assay of the exchange of radiolabeled cholesteryl esters between LDL and HDL added to plasma or its fractions. Although this assay is based on isotopic exchange, mass transfer of cholesteryl esters results from heteroexchange with triglycerides, and therefore reflects the same molecular mechanism as exchange (26) . A similar increase in CETP activity was found in whole plasma and in lipoprotein-free plasma, showing that the increased activity was independent of the endogenous lipoproteins. Although several protein inhibitors of CETP have been identified (27) into apoB-lipoproteins (8 ,g/ml per h) makes only a small contribution to f3-VLDL cholesteryl esters, which are probably synthesized predominantly by intestinal and hepatic acyl CoA:cholesterol acyltransferase (ACAT). On the other hand, in humans organ ACAT is thought to make only a small contribution to plasma cholesteryl esters, which are largely synthesized in HDL and then transferred to apoB-containing lipoproteins (30, 31) . Accordingly, previous studies (32) can be used to calculate a turnover rate of VLDL cholesteryl esters of -17 ,gg/ml plasma per h in human dysbetalipoproteinemia, similar to the rate of transfer of HDL cholesteryl esters into apoB-containing lipoproteins found in the present study (16 /Ag/ml per h). (These calculations assume a cholesteryl ester/protein ratio of 9.3 in rabbit f3-VLDL and a plasma volume of 33 ml/kg (29) . For the dysbetalipoproteinemic patients a VLDL turnover rate of 10 mg apoB/kg per d (32) and a VLDL cholesteryl ester/apoB ratio of 2 (21) were assumed.) Since most of the net transfer of HDL cholesteryl esters into apoB-lipoproteins is actually into VLDL (9), our results suggest that the stimulated transfer of plasma cholesteryl esters makes a major contribution to total VLDL cholesteryl esters (including f3-VLDL) in human dysbetalipoproteinemia. Conversely, the accelerated cholesteryl ester transfer may contribute to the low levels of HDL cholesterol found in the cholesterol-fed rabbit and in human dysbetalipoproteinemia. Our findings in the subjects with dysbetalipoproteinemia are different from those previously reported, where there was low or absent transfer of cholesteryl esters from HDL to apoB-containing lipoproteins (6) . At present we have no explanation for this apparent discrepancy. However, the previous report (6) did not suggest an alternative source for the cholesteryl esters of d < 1.006 lipoproteins in this condition. By contrast, the accelerated transfer process we have described seems to account for the turnover of cholesteryl esters in this fraction. Nonetheless, measurements of cholesteryl ester transfer in incubated plasma may provide only a partial picture of physiological transfer. For example, it is conceivable that in vivo cholesteryl ester transfer processes are much more rapid in certain microenvironments (e.g., into nascent VLDL in the liver, or into triglyceride-rich lipoproteins undergoing lipolysis at the capillary endothelial surface [18] ).
It is possible that other forms of hyperlipidemia, especially those with hypertryglyceridemia and low HDL cholesterol (33) will be found to be associated with accelerated plasma cholesteryl ester transfer. Also, during alimentary lipemia there is stimulation oftransfer of cholesteryl esters from HDL to triglyceridecontaining lipoproteins (9, 34) . In subjects with less efficient clearance of alimentary lipemia, the rates of cholesteryl ester transfer are higher in fasting and lipemic plasma, (4. Tall, unpublished observation) and the fall in HDL cholesteryl ester levels is more marked during alimentary lipemia (35). An inverse relationship between the efficiency of clearance of alimentary lipemia and the levels of fasting HDL lipids has been shown (36) . In alimentary lipemia, dyslipidemia and perhaps other forms of hypertriglyceridemia, increased CETP-mediated cholesteryl ester transfer may serve to link low levels of HDL cholesteryl esters with cholesteryl ester accumulation in atherogenic VLDL and chylomicron remnants (37) . In these hyperlipemic states the increase in cholesteryl ester transfer is secondary to the hyperlipemia, but is thought to result in a redistribution of cholesteryl esters from HDL to triglyceride-rich lipoproteins.
